Literature DB >> 8496688

Mycobacterial virulence. Virulent strains of Mycobacteria tuberculosis have faster in vivo doubling times and are better equipped to resist growth-inhibiting functions of macrophages in the presence and absence of specific immunity.

R J North1, A A Izzo.   

Abstract

The kinetics of growth of two virulent strains of mycobacteria (M. tuberculosis Erdman and M. tuberculosis H37Rv) and two attenuated strains (M. tuberculosis H37Ra and M. bovis Bacillus Calmette-Guerin [BCG]) were studied in the lungs, livers, spleens, and kidneys of severe combined immunodeficient (SCID) mice and of their coisogenic CB-17 immunocompetent counterparts. It was found, in keeping with the findings of earlier investigators (Pierce, C. H., R. J. Dubos, and W. B. Schaefer. 1953. J. Exp. Med. 97:189.), that in immunocompetent mice, virulent organisms grew progressively only in the lungs, whereas the growth of attenuated organisms was controlled in all organs. In SCID mice, in contrast, virulent mycobacteria grew rapidly and progressively in all organs, as did BCG, although at a slower rate. However, H37Ra failed to grow progressively in any organs of SCID mice, unless the mice were treated with hydrocortisone. In fact, hydrocortisone treatment enabled virulent, as well as attenuated, organisms to grow strikingly more rapidly in all organs of SCID mice and in all organs of CB-17 mice. A histological study showed that in SCID mice, multiplication of mycobacteria in the liver occurs in the cytoplasm of macrophages in granulomas and presumably in macrophages in other organs. It is suggested, therefore, that the macrophages of SCID mice possess a glucocorticoid-sensitive mycobacterial mechanism that prevents virulent and avirulent mycobacteria from expressing their true minimal doubling times. In the absence of this mechanism in the lungs of hydrocortisone-treated SCID mice, the doubling times of Erdman, H37Rv, BCG, and H37Ra were 17.7, 17.4, 44.6, and 98.6 h, respectively. The possible importance of a rapid multiplication rate for mycobacterial virulence is discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8496688      PMCID: PMC2191059          DOI: 10.1084/jem.177.6.1723

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  16 in total

1.  Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons--Florida and New York, 1988-1991.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1991-08-30       Impact factor: 17.586

Review 2.  New strategies for leprosy and tuberculosis and for development of bacillus Calmette-Guérin into a multivaccine vehicle.

Authors:  B R Bloom; W R Jacobs
Journal:  Ann N Y Acad Sci       Date:  1989       Impact factor: 5.691

3.  Tuberculosis and human immunodeficiency virus infection: recommendations of the Advisory Committee for the Elimination of Tuberculosis (ACET).

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1989-04-14       Impact factor: 17.586

4.  Evidence for a biphasic memory T-cell response to high dose BCG vaccination in mice.

Authors:  I M Orme
Journal:  Tubercle       Date:  1988-06

5.  Effect of hydrocortisone on macrophage response to lymphokine.

Authors:  H Masur; H W Murray; T C Jones
Journal:  Infect Immun       Date:  1982-02       Impact factor: 3.441

6.  Induction and expression of immunity after BCG immunization.

Authors:  M J Lefford
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

7.  Importance of L3T4+ and Lyt-2+ cells in the immunologic control of infection with Mycobacterium bovis strain bacillus Calmette-Guérin in mice. Assessment by elimination of T cell subsets in vivo.

Authors:  T Pedrazzini; K Hug; J A Louis
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

Review 8.  Vaccines against tuberculosis: the impact of modern biotechnology.

Authors:  S H Kaufmann
Journal:  Scand J Infect Dis Suppl       Date:  1990

9.  T-cell-mediated protection of mice against virulent Mycobacterium tuberculosis.

Authors:  C Leveton; S Barnass; B Champion; S Lucas; B De Souza; M Nicol; D Banerjee; G Rook
Journal:  Infect Immun       Date:  1989-02       Impact factor: 3.441

10.  Requirement for CD4+ cells in resistance to Pneumocystis carinii pneumonia in mice.

Authors:  A G Harmsen; M Stankiewicz
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

View more
  58 in total

Review 1.  The nature and consequence of genetic variability within Mycobacterium tuberculosis.

Authors:  M Kato-Maeda; P J Bifani; B N Kreiswirth; P M Small
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

2.  Construction and phenotypic characterization of an auxotrophic mutant of Mycobacterium tuberculosis defective in L-arginine biosynthesis.

Authors:  Bhavna G Gordhan; Debbie A Smith; Heidi Alderton; Ruth A McAdam; Gregory J Bancroft; Valerie Mizrahi
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

3.  Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis.

Authors:  Seon-Hee Cheon; Beate Kampmann; Amy G Hise; Manijeh Phillips; Ho-Yeon Song; Katherine Landen; Qing Li; Rhonda Larkin; Jerrold J Ellner; Richard F Silver; Daniel F Hoft; Robert S Wallis
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

4.  Complete annotated genome sequence of Mycobacterium tuberculosis Erdman.

Authors:  Tohru Miyoshi-Akiyama; Kazunori Matsumura; Hiroki Iwai; Keiji Funatogawa; Teruo Kirikae
Journal:  J Bacteriol       Date:  2012-05       Impact factor: 3.490

5.  Does M. tuberculosis genomic diversity explain disease diversity?

Authors:  Mireilla Coscolla; Sebastien Gagneux
Journal:  Drug Discov Today Dis Mech       Date:  2010

6.  Artemisia annua and Artemisia afra extracts exhibit strong bactericidal activity against Mycobacterium tuberculosis.

Authors:  Maria Carla Martini; Tianbi Zhang; John T Williams; Robert B Abramovitch; Pamela J Weathers; Scarlet S Shell
Journal:  J Ethnopharmacol       Date:  2020-07-27       Impact factor: 4.360

7.  A reduced antigen load in vivo, rather than weak inflammation, causes a substantial delay in CD8+ T cell priming against Mycobacterium bovis (bacillus Calmette-Guérin).

Authors:  Marsha S Russell; Monica Iskandar; Oksana L Mykytczuk; John H E Nash; Lakshmi Krishnan; Subash Sad
Journal:  J Immunol       Date:  2007-07-01       Impact factor: 5.422

8.  Importance of T cells, gamma interferon, and tumor necrosis factor in immune control of the rapid grower Mycobacterium abscessus in C57BL/6 mice.

Authors:  Martin Rottman; Emilie Catherinot; Patrick Hochedez; Jean-François Emile; Jean-Laurent Casanova; Jean-Louis Gaillard; Claire Soudais
Journal:  Infect Immun       Date:  2007-09-17       Impact factor: 3.441

9.  Virulence ranking of some Mycobacterium tuberculosis and Mycobacterium bovis strains according to their ability to multiply in the lungs, induce lung pathology, and cause mortality in mice.

Authors:  P L Dunn; R J North
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

10.  Opposing effects of interferon-gamma on iNOS and interleukin-10 expression in lipopolysaccharide- and mycobacterial lipoarabinomannan-stimulated macrophages.

Authors:  T I Roach; C H Barton; D Chatterjee; F Y Liew; J M Blackwell
Journal:  Immunology       Date:  1995-05       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.